To the Editor:

Asthma is a chronic disease, characterised by variable airflow obstruction and airway inflammation \[[@C1]\]. Small airways are thought to be a major site of pathology in asthma \[[@C2], [@C3]\]. There are different tools to assess small airways dysfunction (SAD), such as spirometry, body plethysmography, impulse oscillometry (IOS), multiple-breath nitrogen washout (MBNW), alveolar fraction of exhaled nitric oxide (*F*~ENO~) and gas trapping assessed by high-resolution computed tomography (CT). However, there is no golden standard and some tests are difficult to perform \[[@C2], [@C3]\]. Particles in exhaled air (PExA) is a recently developed technique with the potential to identify SAD phenotypes in asthma \[[@C4], [@C5]\]. PExA measurements are noninvasive and easy for subjects to perform, even in severely obstructed patients. PExA captures the aerosol from exhaled breath, and specifically those endogenously generated particles in the size range 0.5--4 µm that are formed during airway closure and reopening. These particles contain water and nonvolatile material originating from the respiratory tract lining fluid \[[@C6]\]. It is thought that SAD leads to impaired reopening of airways or altered composition of the respiratory tract lining fluid, causing fewer particles to be formed \[[@C7]\]. Therefore, severity of SAD is expected to be associated with a reduction of particles measured by PExA.

Some patients with asthma outgrow their disease and reach clinical asthma remission (ClinR); these individuals experience no asthma symptoms even without using asthma medication. Patients in ClinR, however, might still have (asymptomatic) bronchial hyperresponsiveness (BHR) or impaired lung function \[[@C8]--[@C10]\]. B[roekema]{.smallcaps} *et al*. \[[@C11]\] demonstrated that subjects in ClinR still had ongoing airway inflammation. In contrast, a smaller subset of asthma remission subjects may lack BHR and regain normal lung function, *i.e.* complete asthma remission (ComR) \[[@C10]\].

We hypothesised that more SAD leads to decreased exhalation of PExA particles and that this SAD is still present in ClinR but absent in ComR subjects. Therefore, we compared exhaled PExA mass between ClinR and ComR subjects in relation to asthma patients and healthy controls. The second aim of this study was to investigate how PExA mass is associated with other measures of small and large airways function in these groups.

The study protocol was approved by the local ethical committee and all subjects gave informed consent (NL53173.042.15; Groningen, the Netherlands). The included subjects were divided over four groups: the first three groups were subjects with childhood-onset asthma that 1) persisted (PersA; subjects with wheezing and/or asthma attacks, asthma medication use, and a provocative concentration causing a 20% fall in forced expiratory volume in 1 s (PC~20~) for methacholine of \<8 mg·mL^−1^ with 120 s tidal breathing), or that 2) had gone into clinical asthma remission (ClinR; subjects without wheezing/asthma attacks, no use of asthma medication in the last 3 years, with a documented history of asthma according to Global Initiative for Asthma guidelines, a forced expiratory volume in 1 s (FEV~1~) \<80% predicted and/or PC~20~ methacholine \<8 mg·mL^−1^), or 3) into complete asthma remission (ComR; similar to ClinR, but with an FEV~1~ ≥80% pred, PC~20~ methacholine ≥8 mg·mL^−1^ and PC~20~ AMP ≥320 mg·mL^−1^); the fourth group was healthy controls (Ctrl; similar to ComR, but without any history of asthma or use of asthma medication). All subjects were aged 40--65 years and were either never- or ex-smokers with a smoking history \<10 pack-years. Subjects were extensively characterised with the following tests: spirometry, body plethysmography, IOS, *F*~ENO~, MBNW, provocation tests, blood tests, sputum induction and CT scans. PersA subjects were withdrawn from inhaled corticosteroids 6 weeks prior to the clinical characterisation.

PExA mass was collected using the PExA 2.0 device \[[@C5]\]. All subjects performed a similar breathing manoeuvre as described by B[ake]{.smallcaps} *et al*. \[[@C6]\]. To account for potential bias effects of circadian rhythm, all PExA measurements were performed in the morning.

Parametric response mapping (PRM) is a voxel-wise image analysis technique that was implemented on the CT scans. PRM data were analysed according to the methods described in the literature \[[@C12], [@C13]\].

Clinical characteristics and PExA mass in the subject groups were compared using independent sample t-test for normally distributed data (including log2-transformed variables), Mann--Whitney U-tests for non-normally distributed data and Fisher\'s exact tests for categorical variables. Likewise, PExA mass was correlated with small and large airway parameters using either Pearson or Spearman tests. Last, a stepwise multivariate regression analysis was performed to assess independent associations with PExA mass.

Clinical characteristics of the subject groups are presented in [table 1](#TB1){ref-type="table"}. ComR subjects were significantly younger than PersA subjects (p=0.027). The FEV~1~ was significantly higher in Ctrl and ComR compared to PersA subjects, and higher in ComR compared to ClinR subjects.

###### 

Clinical characteristics for the subject groups and bivariate correlations between particles in exhaled air (PExA) mass and small and large airways parameters

  **Characteristics**                               **Ctrl**            **ComR**            **ClinR**           **PersA**       **Kruskal--Wallis p-value**
  -------------------------------------------- ------------------- ------------------- ------------------- ------------------- -----------------------------
  **Subjects n**                                       18                  12                  16                  18          
  **Age years**                                    56 (53--61)         46 (43--55)         54 (47--60)         60 (49--63)                 0.044
  **Female**                                        6 (33.3)            4 (33.3)            7 (43.8)            7 (38.9)                 0.918^¶^
  **Smoking pack-years median (min--max)**          0 (0--5)            0 (0--6)            0 (0--1)            0 (0--2)                   0.104
  **FEV~1~ % pred**                                113.6±12.0           108.1±9.5           84.5±23.1           81.3±17.2                 \<0.001
  **PC~20~ methacholine**                              \>8                 \>8           0.8 (0.1--2.8)      0.6 (0.3--2.2)    
  **PExA mass ng·L^−1^**                        5.68 (3.01--9.57)   4.87 (2.90--6.45)   3.15 (0.71--5.63)   2.67 (0.49--4.02)            0.017^+^
                                                                                                                               
  **Parameter**                                     **Test**           **R-value**         **p-value**                         
                                                                                                                               
  **Age years**                                     Spearman              0.095               0.455                            
  **Body mass index kg·m^−2^**                      Spearman             −0.203               0.107                            
  **Inflammatory**                                                                                                             
   Blood eosinophils ×10^9^ cells·L^−1^ ^\#^         Pearson             −0.182               0.154                            
   Sputum eosinophil differentiation %              Spearman             −0.449               0.013                            
  **Large**                                                                                                                    
   Reversibility pre--post %                        Spearman             −0.469              \<0.001                           
   PC~20~ methacholine slope  mg·mL^−1^ ^\#^         Pearson             −0.483              \<0.001                           
   PC~20~ AMP slope mg·mL^−1^                       Spearman             −0.441               0.001                            
   FEV~1~/FVC ratio pre-salbutamol %                Spearman              0.355               0.004                            
   FEV~1~ % pred pre-salbutamol                      Pearson              0.417               0.001                            
   IOS *R*~20~ Hz                                    Pearson             −0.386               0.002                            
  **Small**                                                                                                                    
   IOS *R*~5~--*R*~20~ Hz                           Spearman             −0.308               0.014                            
   IOS AX Hz·kPa·L^−1^                              Spearman             −0.342               0.006                            
   RV % pred                                        Spearman             −0.431              \<0.001                           
   RV/TLC % pred                                    Spearman             −0.340               0.006                            
   MBNW S~cond~×*V*~T~                              Spearman             −0.380               0.003                            
   MBNW S~acin~×*V*~T~                              Spearman             −0.250               0.056                            
   FEF~25--75%~ % pred                               Pearson              0.340               0.006                            
   Alveolar *F*~ENO~ ppb                            Spearman             −0.254               0.100                            
   CT PRM-fSAD %                                    Spearman             −0.051               0.717                            
   CT PRM inferior to superior  gradient ΔHU         Pearson             −0.197               0.152                            

Data are presented as median (interquartile range), n (%) or mean±[sd]{.smallcaps}, unless otherwise stated. Ctrl: healthy controls; ComR: complete asthma remission subjects; ClinR: clinical asthma remission subjects; PersA: persistent asthma patients; FEV~1~: forced expiratory volume in 1 s; PC~20~: provocative concentration causing a 20% fall in FEV~1~; FVC: forced vital capacity; IOS: impulse oscillometry; *R*~20~: resistance at 20 Hz; *R*~5~: resistance at 5 Hz; AX: area of reactance; RV: residual volume; TLC: total lung capacity; MBNW: multiple-breath nitrogen washout; S~cond~: conductive ventilation heterogeneity; S~acin~: acinar ventilation heterogeneity; *V*~T~: tidal volume; FEF~25--75%~: forced expiratory flow at 25--75% of the pulmonary volume; *F*~ENO~: fraction of exhaled nitric oxide; CT PRM: computed tomography parametric response mapping; fSAD: functional small airways disease. ^\#^: data were log2-transformed to obtain normal distribution; ^¶^: p-value based on Chi-squared test; ^+^: p-value based on ANOVA.

PExA mass was significantly lower in PersA compared to ComR and Ctrl subjects (p=0.028 and p=0.003, respectively) ([figure 1](#F1){ref-type="fig"}). In addition, PExA mass was significantly lower in ClinR compared to Ctrl subjects (p=0.018). Comparison of particle size distribution per group did not yield additional information. This is the first study investigating exhaled particles in asthma remission subjects, showing a similar PExA mass in ComR compared to healthy controls and a decrease in PExA mass in ClinR compared to healthy controls, even though these individuals experience no wheeze or asthma attacks. Our findings are in concordance with the previously stated hypothesis that more SAD leads to decreased exhalation of particles. The fact that ClinR subjects exhale fewer particles suggests that these subjects still have ongoing SAD similar to persistent asthmatics. In contrast, ComR subjects exhale similar amounts of particles compared to healthy controls, possibly due to outgrown SAD. Next, we assessed the correlations between PExA mass and known small and large airway parameters. Results of these bivariate correlations are presented in [table 1](#TB1){ref-type="table"}. Increased PExA mass was associated with less severe BHR and parameters of both large airway function (higher FEV~1~ % pred and higher ratio of FEV~1~ to forced vital capacity (FVC)) and small airway function (higher forced expiratory flow at 25--75% of the pulmonary volume % pred, less hyperinflation as reflected by lower residual volume % pred, lower IOS resistance at 5 Hz minus resistance at 20 Hz (*R*~5~−*R*~20~) and decreased MBNW conductive ventilation heterogeneity multiplied by tidal volume (S~cond~×*V*~T~)). No correlation with PExA mass and PRM-defined (functional) small airways disease was observed. Finally, a stepwise multiple regression analysis was performed, including all variables significantly associated with PExA mass in the bivariate analysis ([table 1](#TB1){ref-type="table"}). This analysis showed that MBNW S~cond~×*V*~T~ was independently associated with PExA mass. FIGURE 1Particles in exhaled air (PExA) mass per subject group. Independent sample t-test p-values are shown. Ctrl: healthy controls (n=18); ComR: complete asthma remission subjects (n=12); ClinR: clinical asthma remission subjects (n=16); PersA: persistent asthma patients (n=18).

S[oares]{.smallcaps} *et al*. \[[@C4]\] found a correlation between mean number of particles per exhalation and FEV~1~/FVC ratio (R=0.246, p=0.021), and between surfactant A PExA concentration and *R*~5~−*R*~20~ (R=0.257, p\<0.05). In accordance with these findings of S[oares]{.smallcaps} *et al*. \[[@C4]\], we show that increased PExA mass is associated with better function of both the large and the small airways.

In conclusion, PExA mass can distinguish asthmatics from healthy individuals. In addition, we show that subjects with complete, but not clinical, asthma remission exhale more PExA mass compared to asthma subjects. Our findings are in concordance with previous studies showing that decreased PExA mass is associated with more severe obstructive pulmonary disease \[[@C7], [@C14]\]. These results reinforce the theory that clinical asthma remission subjects still have ongoing SAD and that subjects in complete asthma remission have completely outgrown their disease \[[@C10]\]. Our observations demonstrate that higher PExA mass is not only related to better large airway function, but also independently associated with SAD as reflected by S~cond~. This indicates that PExA mass could potentially be used as a tool to assess SAD. Future research should focus on exploring the composition of exhaled particles to gain more insight into the pathophysiology of SAD in asthma persistence and remission.
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